6600 Stock Overview
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally.
SciClone Pharmaceuticals (Holdings) Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$6.11|
|52 Week High||HK$8.98|
|52 Week Low||HK$5.65|
|1 Month Change||-1.77%|
|3 Month Change||-10.67%|
|1 Year Change||-26.83%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-67.50%|
Recent News & Updates
Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)Dec 02
We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) EarningsOct 04
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching EarningsJul 27
An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% UndervaluedJun 02
|6600||HK Pharmaceuticals||HK Market|
Return vs Industry: 6600 underperformed the Hong Kong Pharmaceuticals industry which returned -6.7% over the past year.
Return vs Market: 6600 underperformed the Hong Kong Market which returned -20.8% over the past year.
|6600 Average Weekly Movement||5.1%|
|Pharmaceuticals Industry Average Movement||7.6%|
|Market Average Movement||8.0%|
|10% most volatile stocks in HK Market||14.8%|
|10% least volatile stocks in HK Market||4.0%|
Stable Share Price: 6600 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 6600's weekly volatility (5%) has been stable over the past year.
About the Company
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company’s proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome.
SciClone Pharmaceuticals (Holdings) Limited Fundamentals Summary
|6600 fundamental statistics|
Is 6600 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6600 income statement (TTM)|
|Cost of Revenue||CN¥641.03m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||1.23|
|Net Profit Margin||31.28%|
How did 6600 perform over the long term?See historical performance and comparison